AIM Stock Forecast: AIM ImmunoTech, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for AIM ImmunoTech, Inc. is $4.25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 33 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores AIM ImmunoTech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (73): Analysts have, on balance, been raising their forecasts.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AIM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AIM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | Ascendiant Capital | Maintains | Buy | — |
| 1 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 10 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 3 Oct 2025 | Ascendiant Capital | Maintains | Buy | — |
| 10 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 22 Oct 2024 | Maxim Group | Maintains | Buy | — |
| 3 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 10 Oct 2019 | Maxim Group | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AIM.
This page is one stock. Monday covers all of them.
AIM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AIM vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, AIM ImmunoTech, Inc. returned −90.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AIM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 47.2×
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 5% of US stocks
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 81.8%
- Operating margin
- —
- Net margin
- —
Higher than 92% of US stocks
- Return on equity
- −2382.3%
- Return on assets
- −82.6%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AIM ImmunoTech, Inc. has a market value of $4.8M.
Revenue in the twelve months to 31 Mar 2026: $94K. The latest quarter grew 37.5% year on year.
Net income over the same four quarters: −$13.3M, a −14123.4% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$11.7M.
AIM ImmunoTech, Inc. employs 19 people — $5K of revenue per employee.
Data provided by Twelve Data
AIM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AIM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own AIM ImmunoTech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AIM
What is the AIM stock price forecast for 2026-2027?
The median 12-month analyst price target for AIM ImmunoTech, Inc. is $4.25, with estimates ranging from $1.5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AIM stock a buy right now?
Of the 2 analysts covering AIM ImmunoTech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AIM ImmunoTech, Inc. 33 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AIM?
As at 21 Nov 2026, AIM ImmunoTech, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (73 of 100).
Will AIM stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $4.25, and Ticker Nerd's factor model ranks AIM ImmunoTech, Inc. 33 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AIM stock forecast for 2030?
No analyst covering AIM ImmunoTech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $7 over the next 12 months.
How has AIM stock performed over the past year?
AIM ImmunoTech, Inc. returned -90.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does AIM ImmunoTech, Inc. do?
AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders. Its current portfolio centers on Ampligen, an investigational double-stranded RNA therapy being evaluated in clinical studies for oncology and selected viral and immune conditions, and Alferon N Injection, a natural-source interferon product used for specific approved indications.
About AIM ImmunoTech, Inc.
AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders. Its current portfolio centers on Ampligen, an investigational double-stranded RNA therapy being evaluated in clinical studies for oncology and selected viral and immune conditions, and Alferon N Injection, a natural-source interferon product used for specific approved indications. The company works across preclinical and clinical research, with an emphasis on immune system activation, antiviral defense, and combination approaches for difficult-to-treat diseases. AIM ImmunoTech serves the biopharmaceutical sector by advancing specialized therapies that target areas with limited treatment options, making it a recognized participant in immunotherapy and antiviral drug development.
CEO Mr. Thomas K. Equels Esq., J.D., M.S. · 19 employees · United States · https://aimimmuno.com